In its first-quarter 2025 investor letter, Upslope Capital Management highlighted stocks such as Charles River Laboratories International, Inc. (NYSE:CRL). Charles River Laboratories International ...

The company initiated three clinical trials assessing dry eye disease symptoms in response to the CRL back in 2023. It achieved the primary endpoint in the first dry eye chamber clinical trial ...

In trading on Tuesday, shares of Charles River Laboratories International Inc. (Symbol: CRL) entered into oversold territory, hitting an RSI reading of 29.8, after changing hands as low as $105.18 ...

In this article, we are going to take a look at where Charles River Laboratories International, Inc. (NYSE:CRL) stands against other mid-cap stocks insiders were buying in Q1 2025. Stock markets ...